| Management of virologic failure and HIV drug resistance SM McCluskey, MJ Siedner, VC Marconi Infectious Disease Clinics 33 (3), 707-742, 2019 | 72 | 2019 |
| Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era SM McCluskey, T Pepperrell, A Hill, WDF Venter, RK Gupta, MJ Siedner Aids 35 (Supplement 2), S127-S135, 2021 | 31 | 2021 |
| Brief report: appraising viral load thresholds and adherence support recommendations in the World Health Organization guidelines for detection and management of virologic failure SM McCluskey, II Yap Boum, N Musinguzi, JE Haberer, JN Martin, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 76 (2), 183-187, 2017 | 22 | 2017 |
| Serial procalcitonin as a predictor of bacteremia and need for intensive care unit care in adults with pneumonia, including those with highest severity: a prospective cohort study SM McCluskey, P Schuetz, MS Abers, B Bearnot, ME Morales, D Hoffman, ... Open forum infectious diseases 4 (1), ofw238, 2017 | 22 | 2017 |
| The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost … MJ Siedner, MB Bwana, MYS Moosa, M Paul, S Pillay, S McCluskey, ... HIV clinical trials 18 (4), 149-155, 2017 | 20 | 2017 |
| Resistance testing for management of HIV virologic failure in sub-Saharan Africa: an unblinded randomized controlled trial MJ Siedner, MYS Moosa, S McCluskey, RF Gilbert, S Pillay, I Aturinda, ... Annals of internal medicine 174 (12), 1683-1692, 2021 | 18 | 2021 |
| Coronavirus Disease 2019 (COVID-19) diagnostic clinical decision support: a pre-post implementation study of CORAL (COvid Risk cALculator) CM Dugdale, DM Rubins, H Lee, SM McCluskey, ET Ryan, CN Kotton, ... Clinical Infectious Diseases 73 (12), 2248-2256, 2021 | 13 | 2021 |
| Increasing prevalence of HIV pretreatment drug resistance in women but not men in rural Uganda during 2005–2013 SM McCluskey, GQ Lee, K Kamelian, A Kembabazi, N Musinguzi, ... AIDS Patient Care and STDs 32 (7), 257-264, 2018 | 13 | 2018 |
| Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure SM McCluskey, K Govender, J Adamson, M Gandhi, MA Spinelli, ... AIDS 37 (7), 1109-1113, 2023 | 10 | 2023 |
| Clinical, laboratory, and radiologic characteristics of patients with initial false-negative SARS-CoV-2 nucleic acid amplification test results CM Dugdale, JJ Chiosi, JE Lazarus, SM McCluskey, AL Ciaranello, ... Open Forum Infect Dis 8 (1), 2020 | 10 | 2020 |
| Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda SM McCluskey, K Kamelian, N Musinguzi, S Kigozi, II Yap Boum, ... AIDS 35 (7), 1083-1089, 2021 | 8 | 2021 |
| Clinical, laboratory, and radiologic characteristics of patients with initial false-negative severe acute respiratory syndrome coronavirus 2 nucleic acid amplification test results CM Dugdale, MN Anahtar, JJ Chiosi, JE Lazarus, SM McCluskey, ... Open Forum Infectious Diseases 8 (1), ofaa559, 2021 | 8 | 2021 |
| Outcomes from an infectious disease physician-guided evaluation of hospitalized persons under investigation for coronavirus disease 2019 (COVID-19) at a large US academic … CM Dugdale, SE Turbett, SM McCluskey, KC Zachary, ES Shenoy, ... Infection Control & Hospital Epidemiology 42 (3), 344-347, 2021 | 5 | 2021 |
| Case 22-2022: a 34-year-old woman with cavitary lung lesions D Restrepo, A Haramati, SM McCluskey, JA Branda New England Journal of Medicine 387 (3), 261-269, 2022 | 4 | 2022 |
| Drug resistance and use of long-acting ART J da Silva, M Siedner, S McCluskey, N Chandiwana, F Venter, E Raizes The Lancet HIV 9 (6), e374-e375, 2022 | 4 | 2022 |
| Who’s slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first‐line HIV treatment in … Z Reynolds, SM McCluskey, MYS Moosa, RF Gilbert, S Pillay, I Aturinda, ... HIV medicine 23 (5), 474-484, 2022 | 4 | 2022 |
| Brief report: should Abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? GQ Lee, S McCluskey, II Yap Boum, PW Hunt, JN Martin, DR Bangsberg, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 76 (2), 188-192, 2017 | 3 | 2017 |
| Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review C Chu, K Tao, V Kouamou, A Avalos, J Scott, PM Grant, SY Rhee, ... Viruses 16 (3), 399, 2024 | 2 | 2024 |
| Seemingly Unrelated Regression Analysis of the Cost and Health-Related Quality of Life Outcomes of the REVAMP Randomized Clinical Trial TA Rautenberg, SK Ng, G George, MYS Moosa, SM McCluskey, ... Value in health regional issues 35, 42-47, 2023 | 2 | 2023 |
| 48-week outcomes after programmatic transition to dolutegravir in Uganda. Poster Abstract# 487 SM Mccluskey, W Muyindike, V Nanfuka, D Omoding, N Komukama, ... Conference on Retroviruses and Opportunistic Infections, 2022 | 2 | 2022 |
